{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:09:29Z","timestamp":1792649369425,"version":"4.5.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40257-019-00488-w","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T06:03:14Z","timestamp":1575439394000},"page":"173-225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":187,"title":["Melasma Treatment: An Evidence-Based Review"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3425-8224","authenticated-orcid":false,"given":"Jacqueline","family":"McKesey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tovar-Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit G.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"issue":"1","key":"488_CR1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijwd.2017.11.003","volume":"4","author":"J Jiang","year":"2017","unstructured":"Jiang J, Akinseye O, Tovar-Garza A, Pandya AG. The effect of melasma on self-esteem: a pilot study. Int J Womens Dermatol. 2017;4(1):38\u201342.","journal-title":"Int J Womens Dermatol."},{"key":"488_CR2","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/archderm.1995.01690240119022","volume":"131","author":"PE Grimes","year":"1995","unstructured":"Grimes PE. Melasma: etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453\u20137.","journal-title":"Arch Dermatol."},{"key":"488_CR3","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1468-3083.2009.03295.x","volume":"23","author":"JP Ortonne","year":"2009","unstructured":"Ortonne JP, Arellano I, Berneburg M, et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatol Venereol. 2009;23:1254\u201362.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"488_CR4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/jid.1962.136","volume":"39","author":"MA Pathak","year":"1962","unstructured":"Pathak MA, Riley FC, Fitzpatrick TB. Melanogenesis in human skin following exposure to long ultraviolet and visible light. J Investig Dermatol. 1962;39:435.","journal-title":"J Investig Dermatol."},{"key":"488_CR5","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0190-9622(81)70071-9","volume":"4","author":"NP Sanchez","year":"1981","unstructured":"Sanchez NP, Pathak MA, Sato S. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol. 1981;4:698\u2013709.","journal-title":"J Am Acad Dermatol."},{"key":"488_CR6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/jama.1967.03120090043007","volume":"199","author":"S Resnik","year":"1967","unstructured":"Resnik S. Melasma induced by oral contraceptive drugs. JAMA. 1967;199:601\u20135.","journal-title":"JAMA."},{"key":"488_CR7","first-page":"103","volume":"20","author":"HA Ponzio","year":"2007","unstructured":"Ponzio HA, Favaretto AL, Rivitti EA. Proposal of a quantitative method to describe melasma distribution in women. J Cosmet Dermatol. 2007;20:103\u201311.","journal-title":"J Cosmet Dermatol."},{"issue":"7","key":"488_CR8","first-page":"CD003583","volume":"7","author":"R Rajaratnam","year":"2010","unstructured":"Rajaratnam R, Halpern J, Salim A, Emmett C. Interventions for melasma. Cochrane Database Syst Rev. 2010;7(7):CD003583.","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"488_CR9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1529-8019.2007.00144.x","volume":"20","author":"ZD Draelos","year":"2007","unstructured":"Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007;20(5):308\u201313.","journal-title":"Dermatol Ther."},{"issue":"2","key":"488_CR10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1473-2165.2005.40202.x","volume":"4","author":"W Westerhof","year":"2005","unstructured":"Westerhof W, Kooyers TJ. Hydroquinone and its analogues in dermatology\u2014a potential health risk. J Cosmet Dermatol. 2005;4(2):55\u20139.","journal-title":"J Cosmet Dermatol."},{"issue":"7","key":"488_CR11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1468-3083.2006.01670.x","volume":"20","author":"JJ Nordlund","year":"2006","unstructured":"Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. J Eur Acad Dermatol Venereol. 2006;20(7):781\u20137.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"488_CR12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/09546630050517333","volume":"11","author":"SBP Ennes","year":"2000","unstructured":"Ennes SBP, Paschoalick RC, De Avelar Alchorne MM. A double-blind comparative placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma. J Dermatol Treat. 2000;11:173\u20139.","journal-title":"J Dermatol Treat."},{"issue":"1","key":"488_CR13","first-page":"92","volume":"32","author":"M V\u00e1zquez","year":"1983","unstructured":"V\u00e1zquez M, S\u00e1nchez JL. The efficacy of a broad-spectrum sunscreen in the treatment of melasma. Cutis. 1983;32(1):92 (95\u201396).","journal-title":"Cutis."},{"key":"488_CR14","first-page":"58","volume":"143","author":"VM Verallo-Rowell","year":"1989","unstructured":"Verallo-Rowell VM, Verallo V, Graupe K, Lopez-Villafuerte L, Garcia-Lopez M. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl (Stockh). 1989;143:58\u201361.","journal-title":"Acta Derm Venereol Suppl (Stockh)."},{"key":"488_CR15","first-page":"680","volume":"5","author":"A Sivayathorn","year":"1995","unstructured":"Sivayathorn A, Verallo-Rowell V, Graupe K. 20% azelaic acid cream in the topical treatment of melasma: a double-blind comparison with 2% hydroquinone. Eur J Dermatol. 1995;5:680\u20134.","journal-title":"Eur J Dermatol."},{"issue":"12","key":"488_CR16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1365-4362.1991.tb04362.x","volume":"30","author":"LM Bali\u00f1a","year":"1991","unstructured":"Bali\u00f1a LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol. 1991;30(12):893\u20135.","journal-title":"Int J Dermatol."},{"issue":"4","key":"488_CR17","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1473-2165.2011.00580.x","volume":"10","author":"S Farshi","year":"2011","unstructured":"Farshi S. Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma. J Cosmet Dermatol. 2011;10(4):282\u20137.","journal-title":"J Cosmet Dermatol."},{"issue":"3","key":"488_CR18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000065851","volume":"205","author":"R Sarkar","year":"2002","unstructured":"Sarkar R, Bhalla M, Kanwar AJ. A comparative study of 20% azelaic acid cream monotherapy versus a sequential therapy in the treatment of melasma in dark-skinned patients. Dermatology. 2002;205(3):249\u201354.","journal-title":"Dermatology."},{"issue":"4","key":"488_CR19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000069943","volume":"206","author":"CH Huh","year":"2003","unstructured":"Huh CH, Seo KI, Park JY, Lim JG, Eun HC, Park KC. A randomized, double-blind, placebo-controlled trial of vitamin C iontophoresis in melasma. Dermatology. 2003;206(4):316\u201320.","journal-title":"Dermatology."},{"issue":"8","key":"488_CR20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1365-4632.2004.02134.x","volume":"43","author":"LE Espinal-Perez","year":"2004","unstructured":"Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol. 2004;43(8):604\u20137.","journal-title":"Int J Dermatol."},{"issue":"5","key":"488_CR21","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1365-2133.2007.07814.x","volume":"156","author":"A Khemis","year":"2007","unstructured":"Khemis A, Kaiafa A, Queille-Roussel C, Duteil L, Ortonne JP. Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial. Br J Dermatol. 2007;156(5):997\u20131004.","journal-title":"Br J Dermatol."},{"issue":"4","key":"488_CR22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1346-8138.2010.00787.x","volume":"37","author":"SY Huh","year":"2010","unstructured":"Huh SY, Shin JW, Na JI, Huh CH, Youn SW, Park KC. Efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial. J Dermatol. 2010;37(4):311\u20135.","journal-title":"J Dermatol."},{"key":"488_CR23","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1242\/jcs.107.4.1095","volume":"107","author":"C Romero","year":"1994","unstructured":"Romero C, Aberdam E, Larnier C, Ortonne JP. Retinoic acid as modulator of UVB-induced melanocyte differentiation. Involvement of the melanogenic enzyme\u2019s expression. J Cell Sci. 1994;107:1095\u2013103.","journal-title":"J Cell Sci."},{"key":"488_CR24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1529-8019.2006.00085.x","volume":"19","author":"JP Ortonne","year":"2006","unstructured":"Ortonne JP. Retinoid therapy of pigmented disorders. Dermatol Ther. 2006;19:280\u20138.","journal-title":"Dermatol Ther."},{"issue":"4","key":"488_CR25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2133.1993.tb03169.x","volume":"129","author":"CE Griffiths","year":"1993","unstructured":"Griffiths CE, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol. 1993;129(4):415\u201321.","journal-title":"Br J Dermatol."},{"issue":"6","key":"488_CR26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/archderm.1994.01690060057005","volume":"130","author":"CK Kimbrough-Green","year":"1994","unstructured":"Kimbrough-Green CK, Griffiths CE, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, Ellis CN, Voorhees JJ. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch Dermatol. 1994;130(6):727\u201333.","journal-title":"Arch Dermatol."},{"issue":"9","key":"488_CR27","first-page":"868","volume":"82","author":"V Leenutaphong","year":"1999","unstructured":"Leenutaphong V, Nettakul A, Rattanasuwon P. Topical isotretinoin for melasma in Thai patients: a vehicle-controlled clinical trial. J Med Assoc Thai. 1999;82(9):868\u201375.","journal-title":"J Med Assoc Thai."},{"issue":"8","key":"488_CR28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1346-8138.2002.tb00324.x","volume":"29","author":"S Dogra","year":"2002","unstructured":"Dogra S, Kanwar AJ, Parsad D. Adapalene in the treatment of melasma: a preliminary report. J Dermatol. 2002;29(8):539\u201340.","journal-title":"J Dermatol."},{"issue":"4","key":"488_CR29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/jocd.12110","volume":"13","author":"MT Truchuelo","year":"2014","unstructured":"Truchuelo MT, Jim\u00e9nez N, Ja\u00e9n P. Assessment of the efficacy and tolerance of a new combination of retinoids and depigmenting agents in the treatment of melasma. J Cosmet Dermatol. 2014;13(4):261\u20138.","journal-title":"J Cosmet Dermatol."},{"key":"488_CR30","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/jid.2011.476","volume":"132","author":"F Liebel","year":"2012","unstructured":"Liebel F, Kaur S, Ruvolo E, Kollias N, Southall MD. Irradiation of skin with visible light induces reactive oxygen species and matrix-degrading enzymes. J Investig Dermatol. 2012;132:1901\u20137.","journal-title":"J Investig Dermatol"},{"key":"488_CR31","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/jid.2010.95","volume":"130","author":"BH Mahmoud","year":"2010","unstructured":"Mahmoud BH, Ruvolo E, Hexsel CL, et al. Impact of long-wavelength UVA and visible light on melanocompetent skin. J Investig Dermatol. 2010;130:2092\u20137.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"488_CR32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/phpp.12086","volume":"30","author":"JP Castanedo-Cazares","year":"2014","unstructured":"Castanedo-Cazares JP, Hernandez-Blanco D, Carlos-Ortega B, Fuentes-Ahumada C, Torres-\u00c1lvarez B. Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial. Photodermatol Photoimmunol Photomed. 2014;30(1):35\u201342.","journal-title":"Photodermatol Photoimmunol Photomed."},{"issue":"1","key":"488_CR33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/dsu.12296","volume":"40","author":"A Yousefi","year":"2014","unstructured":"Yousefi A, Khani Khoozani Z, Zakerzadeh Forooshani S, Omrani N, Moini AM, Eskandari Y. Is topical zinc effective in the treatment of melasma? A double-blind randomized comparative study. Dermatol Surg. 2014;40(1):33\u20137.","journal-title":"Dermatol Surg."},{"issue":"8","key":"488_CR34","first-page":"753","volume":"19","author":"B Ebrahimi","year":"2014","unstructured":"Ebrahimi B, Naeini FF. Topical tranexamic acid as a promising treatment for melasma. J Res Med Sci. 2014;19(8):753\u20137.","journal-title":"J Res Med Sci."},{"issue":"3","key":"488_CR35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/jocd.12152","volume":"14","author":"M Banihashemi","year":"2015","unstructured":"Banihashemi M, Zabolinejad N, Jaafari MR, Salehi M, Jabari A. Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma. J Cosmet Dermatol. 2015;14(3):174\u20137.","journal-title":"J Cosmet Dermatol."},{"issue":"3","key":"488_CR36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13555-017-0195-0","volume":"7","author":"N Atefi","year":"2017","unstructured":"Atefi N, Dalvand B, Ghassemi M, Mehran G, Heydarian A. Therapeutic effects of topical tranexamic acid in comparison with hydroquinone in treatment of women with Melasma. Dermatol Ther (Heidelb). 2017;7(3):417\u201324.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"6","key":"488_CR37","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/14764172.2018.1427869","volume":"20","author":"V Laothaworn","year":"2018","unstructured":"Laothaworn V, Juntongjin P. Topical 3% tranexamic acid enhances the efficacy of 1064-nm Q-switched neodymium-doped yttrium aluminum garnet laser in the treatment of melasma. J Cosmet Laser Ther. 2018;20(6):320\u20135.","journal-title":"J Cosmet Laser Ther."},{"issue":"19","key":"488_CR38","doi-asserted-by":"crossref","first-page":"e6897","DOI":"10.1097\/MD.0000000000006897","volume":"96","author":"Y Xu","year":"2017","unstructured":"Xu Y, Ma R, Juliandri J, Wang X, Xu B, Wang D, Lu Y, Zhou B, Luo D. Efficacy of functional microarray of microneedles combined with topical tranexamic acid for melasma: a randomized, self-controlled, split-face study. Medicine (Baltimore). 2017;96(19):e6897.","journal-title":"Medicine (Baltimore)."},{"issue":"4","key":"488_CR39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/09546634.2017.1392476","volume":"29","author":"N Saki","year":"2018","unstructured":"Saki N, Darayesh M, Heiran A. Comparing the efficacy of topical hydroquinone 2% versus intradermal tranexamic acid microinjections in treating melasma: a split-face controlled trial. J Dermatol Treat. 2018;29(4):405\u201310.","journal-title":"J Dermatol Treat."},{"key":"488_CR40","doi-asserted-by":"crossref","first-page":"8350317","DOI":"10.1155\/2018\/8350317","volume":"2018","author":"Z Tehranchinia","year":"2018","unstructured":"Tehranchinia Z, Saghi B, Rahimi H. Evaluation of therapeutic efficacy and safety of tranexamic acid local infiltration in combination with topical 4% hydroquinone cream compared to topical 4% hydroquinone cream alone in patients with melasma: a split-face study. Dermatol Res Pract. 2018;2018:8350317.","journal-title":"Dermatol Res Pract."},{"issue":"4","key":"488_CR41","first-page":"174","volume":"1","author":"D Steiner","year":"2009","unstructured":"Steiner D, Feola C, Bialeski N, Ayeres de Morais e Silva F, C\u00e9sar Pessanha Antiori A, Alvim Sant\u2019Anna Addor F, Brand\u00e3o Folino B. Study evaluating the efficacy of topical and injected tranexamic acid in treatment of melasma. Surg Cosmet Dermatol. 2009;1(4):174\u20137.","journal-title":"Surg Cosmet Dermatol."},{"issue":"3","key":"488_CR42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/0974-2077.118403","volume":"6","author":"L Budamakuntla","year":"2013","unstructured":"Budamakuntla L, Loganathan E, Suresh DH, Shanmugam S, Suryanarayan S, Dongare A, Venkataramiah LD, Prabhu N. A randomised, open-label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with Melasma. J Cutan Aesthet Surg. 2013;6(3):139\u201343.","journal-title":"J Cutan Aesthet Surg."},{"issue":"1","key":"488_CR43","first-page":"67","volume":"72","author":"SC Taylor","year":"2003","unstructured":"Taylor SC, Torok H, Jones T, Lowe N, Rich P, Tschen E, Menter A, Baumann L, Wieder JJ, Jarratt MM, Pariser D, Martin D, Weiss J, Shavin J, Ramirez N. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72(1):67\u201372.","journal-title":"Cutis."},{"issue":"5","key":"488_CR44","first-page":"592","volume":"4","author":"H Torok","year":"2005","unstructured":"Torok H, Taylor S, Baumann L, Jones T, Wieder J, Lowe N, Jarret M, Rich P, Pariser D, Tschen E, Martin D, Menter A, Weiss J. A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. J Drugs Dermatol. 2005;4(5):592\u20137.","journal-title":"J Drugs Dermatol."},{"issue":"1","key":"488_CR45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1473-2165.2007.00288.x","volume":"6","author":"T Ferreira Cestari","year":"2007","unstructured":"Ferreira Cestari T, Hassun K, Sittart A, de Lourdes Viegas M. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol. 2007;6(1):36\u20139.","journal-title":"J Cosmet Dermatol."},{"issue":"3","key":"488_CR46","first-page":"697","volume":"159","author":"R Chan","year":"2008","unstructured":"Chan R, Park KC, Lee MH, Lee ES, Chang SE, Leow YH, Tay YK, Legarda-Montinola F, Tsai RY, Tsai TH, Shek S, Kerrouche N, Thomas G, Verallo-Rowell V. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol. 2008;159(3):697\u2013703.","journal-title":"Br J Dermatol."},{"issue":"6","key":"488_CR47","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40261-015-0292-8","volume":"35","author":"Z Gong","year":"2015","unstructured":"Gong Z, Lai W, Zhao G, Wang X, Zheng M, Li L, Yang Q, Dang Y, Liu L, Zou Y. Efficacy and safety of fluocinolone acetonide, hydroquinone, and tretinoin cream in Chinese patients with melasma: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study. Clin Drug Investig. 2015;35(6):385\u201395.","journal-title":"Clin Drug Investig."},{"issue":"5","key":"488_CR48","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1468-3083.2011.04135.x","volume":"26","author":"I Arellano","year":"2012","unstructured":"Arellano I, Cestari T, Ocampo-Candiani J, Azulay-Abulafia L, Bezerra Trindade Neto P, Hexsel D, Machado-Pinto J, Mu\u00f1oz H, Rivitti-Machado MC, Sittart JA, Trindade de Almeida AR, Rego V, Paliargues F, Marques-Hassun K. Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity. J Eur Acad Dermatol Venereol. 2012;26(5):611\u20138.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"6","key":"488_CR49","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jaad.2009.06.067","volume":"62","author":"PE Grimes","year":"2010","unstructured":"Grimes PE, Bhawan J, Guevara IL, Col\u00f3n LE, Johnson LA, Gottschalk RW, Pandya AG. Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. J Am Acad Dermatol. 2010;62(6):962\u20137.","journal-title":"J Am Acad Dermatol."},{"issue":"12","key":"488_CR50","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1365-4632.2003.02017.x","volume":"42","author":"IL Guevara","year":"2003","unstructured":"Guevara IL, Pandya AG. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int J Dermatol. 2003;42(12):966\u201372.","journal-title":"Int J Dermatol."},{"issue":"4","key":"488_CR51","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1046\/j.1524-4725.1999.08236.x","volume":"25","author":"JT Lim","year":"1999","unstructured":"Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg. 1999;25(4):282\u20134.","journal-title":"Dermatol Surg."},{"issue":"2","key":"488_CR52","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.1365-4362.2003.01621.x","volume":"42","author":"AL Haddad","year":"2003","unstructured":"Haddad AL, Matos LF, Brunstein F, Ferreira LM, Silva A, Costa D Jr. A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma. Int J Dermatol. 2003;42(2):153\u20136.","journal-title":"Int J Dermatol."},{"key":"488_CR53","first-page":"18","volume":"13","author":"J Francisco-Diaz","year":"2004","unstructured":"Francisco-Diaz J, Cristi-Cataluna I, Cruz DD, Verallo-Rowell VM. A double-blind randomized placebo-controlled trial on the efficacy and safety of botanical extract (Gigawhite_ 5% solution) in the treatment of melasma. J Philos Dermatol Soc. 2004;13:18\u201323.","journal-title":"J Philos Dermatol Soc."},{"key":"488_CR54","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1467-2494.2006.00312.x","volume":"28","author":"L Thirion","year":"2006","unstructured":"Thirion L, Pierard-Franchimont C, Pierard G. Whitening effect of a dermocosmetic formulation: a randomized double-blind controlled study on melasma. Int J Cosmet Sci. 2006;28:263\u20137.","journal-title":"Int J Cosmet Sci."},{"issue":"3","key":"488_CR55","first-page":"s21","volume":"12","author":"ET Makino","year":"2013","unstructured":"Makino ET, Mehta RC, Garruto J, Gotz V, Sigler ML, Herndon JH. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone. J Drugs Dermatol. 2013;12(3):s21\u20136.","journal-title":"J Drugs Dermatol."},{"issue":"3","key":"488_CR56","first-page":"270","volume":"12","author":"GD Monheit","year":"2013","unstructured":"Monheit GD, Dreher F. Comparison of a skin-lightening cream targeting melanogenesis on multiple levels to triple combination cream for melasma. J Drugs Dermatol. 2013;12(3):270\u20134.","journal-title":"J Drugs Dermatol."},{"issue":"1","key":"488_CR57","first-page":"13","volume":"14","author":"M Wanner","year":"2015","unstructured":"Wanner M, Houston N, Javorsky E, Yuan M, Alora-Palli M, Kimball AB. Single blind, randomized, controlled trial of a lightening product with and without iontophoresis versus tretinoin and vehicle for hyperpigmentation. J Drugs Dermatol. 2015;14(1):13\u20138.","journal-title":"J Drugs Dermatol."},{"issue":"2","key":"488_CR58","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/jocd.12201","volume":"15","author":"WO Pratchyapurit","year":"2016","unstructured":"Pratchyapurit WO. Combined use of two formulations containing diacetyl boldine, TGF-\u03b21 biomimetic oligopeptide-68 with other hypopigmenting\/exfoliating agents and sunscreen provides effective and convenient treatment for facial melasma. Either is equal to or is better than 4% hydroquinone on normal skin. J Cosmet Dermatol. 2016;15(2):131\u201344.","journal-title":"J Cosmet Dermatol."},{"issue":"4","key":"488_CR59","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-4362.2000.00943.x","volume":"39","author":"M Amer","year":"2000","unstructured":"Amer M, Metwalli M. Topical liquiritin improves melasma. Int J Dermatol. 2000;39(4):299\u2013301.","journal-title":"Int J Dermatol."},{"issue":"5","key":"488_CR60","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1590\/S0365-05962010000500003","volume":"85","author":"A Costa","year":"2010","unstructured":"Costa A, Mois\u00e9s TA, Cordero T, Alves CR, Marmirori J. Association of emblica, licorice and belides as an alternative to hydroquinone in the clinical treatment of melasma. An Bras Dermatol. 2010;85(5):613\u201320.","journal-title":"An Bras Dermatol."},{"issue":"3","key":"488_CR61","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/jocd.12147","volume":"14","author":"M Morag","year":"2015","unstructured":"Morag M, Nawrot J, Siatkowski I, Adamski Z, Fedorowicz T, Dawid-Pac R, Urbanska M, Nowak G. A double-blind, placebo-controlled randomized trial of Serratulae quinquefoliae folium, a new source of \u03b2-arbutin, in selected skin hyperpigmentation. J Cosmet Dermatol. 2015;14(3):185\u201390.","journal-title":"J Cosmet Dermatol."},{"issue":"9","key":"488_CR62","first-page":"1025","volume":"10","author":"G Alvin","year":"2011","unstructured":"Alvin G, Catambay N, Vergara A, Jamora MJ. A comparative study of the safety and efficacy of 75% mulberry (Morus alba) extract oil versus placebo as a topical treatment for melasma: a randomized, single-blind, placebo-controlled trial. J Drugs Dermatol. 2011;10(9):1025\u201331.","journal-title":"J Drugs Dermatol."},{"issue":"1","key":"488_CR63","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaad.2014.09.011","volume":"72","author":"ZD Draelos","year":"2015","unstructured":"Draelos ZD. A split-face evaluation of a novel pigment-lightening agent compared with no treatment and hydroquinone [published erratum in J Am Acad Dermatol. 2015;72(6):1096]. J Am Acad Dermatol. 2015;72(1):105\u20137.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"488_CR64","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/HNP.0000000000000186","volume":"31","author":"S Khosravan","year":"2017","unstructured":"Khosravan S, Alami A, Mohammadzadeh-Moghadam H, Ramezani V. The effect of topical use of Petroselinum crispum (Parsley) versus that of hydroquinone cream on reduction of epidermal melasma: a randomized clinical trial. Holist Nurs Pract. 2017;31(1):16\u201320.","journal-title":"Holist Nurs Pract."},{"issue":"11","key":"488_CR65","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/ijd.12690","volume":"53","author":"CG Mendoza","year":"2014","unstructured":"Mendoza CG, Singzon IA, Handog EB. A randomized, double-blind, placebo-controlled clinical trial on the efficacy and safety of 3% Rumex occidentalis cream versus 4% hydroquinone cream in the treatment of melasma among Filipinos. Int J Dermatol. 2014;53(11):1412\u20136.","journal-title":"Int J Dermatol."},{"key":"488_CR66","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-5945-12-18","volume":"12","author":"T Altaei","year":"2012","unstructured":"Altaei T. The treatment of melasma by silymarin cream. BMC Dermatol. 2012;12:18.","journal-title":"BMC Dermatol."},{"issue":"4","key":"488_CR67","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3346\/jkms.2002.17.4.518","volume":"17","author":"MH Lee","year":"2002","unstructured":"Lee MH, Kim HJ, Ha DJ, Paik JH, Kim HY. Therapeutic effect of topical application of linoleic acid and lincomycin in combination with betamethasone valerate in melasma patients. J Korean Med Sci. 2002;17(4):518\u201323.","journal-title":"J Korean Med Sci."},{"issue":"2","key":"488_CR68","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/jocd.12089","volume":"13","author":"A Katoulis","year":"2014","unstructured":"Katoulis A, Alevizou A, Soura E, Mantas N, Bozi E, Gregoriou S, Makris M, Rigopoulos D. A double-blind vehicle-controlled study of a preparation containing undecylenoyl phenylalanine 2% in the treatment of melasma in females. J Cosmet Dermatol. 2014;13(2):86\u201390.","journal-title":"J Cosmet Dermatol."},{"issue":"1","key":"488_CR69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bjd.13424","volume":"173","author":"P Mansouri","year":"2015","unstructured":"Mansouri P, Farshi S, Hashemi Z, Kasraee B. Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial. Br J Dermatol. 2015;173(1):209\u201317.","journal-title":"Br J Dermatol."},{"issue":"2","key":"488_CR70","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/09546634.2017.1351608","volume":"29","author":"S Farshi","year":"2018","unstructured":"Farshi S, Mansouri P, Kasraee B. Efficacy of cysteamine cream in the treatment of epidermal melasma, evaluating by Dermacatch as a new measurement method: a randomized double blind placebo controlled study. J Dermatol Treat. 2018;29(2):182\u20139.","journal-title":"J Dermatol Treat."},{"key":"488_CR71","first-page":"4219","volume":"9","author":"H Adalatkhah","year":"2015","unstructured":"Adalatkhah H, Sadeghi-Bazargani H. The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial. Drug Des Dev Ther. 2015;9:4219\u201325.","journal-title":"Drug Des Dev Ther."},{"issue":"1","key":"488_CR72","first-page":"67","volume":"54","author":"G Eshghi","year":"2016","unstructured":"Eshghi G, Khezrian L, Esna Ashari F. Comparison between intralesional triamcinolone and Kligman\u2019s formula in treatment of melasma. Acta Med Iran. 2016;54(1):67\u201371.","journal-title":"Acta Med Iran."},{"issue":"3","key":"488_CR73","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1524-4725.1997.tb00016.x","volume":"23","author":"JT Lim","year":"1997","unstructured":"Lim JT, Tham SN. Glycolic acid peels in the treatment of melasma among Asian women. Dermatol Surg. 1997;23(3):177\u20139.","journal-title":"Dermatol Surg."},{"key":"488_CR74","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1001\/archderm.138.12.1578","volume":"138","author":"ME Hurley","year":"2002","unstructured":"Hurley ME, Guevara IL, Gonzales RM, Pandya AG. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol. 2002;138:1578\u201382.","journal-title":"Arch Dermatol."},{"issue":"4","key":"488_CR75","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1524-4725.2010.01481.x","volume":"36","author":"T Ilknur","year":"2010","unstructured":"Ilknur T, Bi\u00e7ak M\u00dc, Demirta\u015fo\u011flu M, \u00d6zkan \u015e. Glycolic acid peels versus amino fruit acid peels in the treatment of melasma. Dermatol Surg. 2010;36(4):490\u20135.","journal-title":"Dermatol Surg."},{"issue":"4","key":"488_CR76","first-page":"447","volume":"76","author":"R Kumari","year":"2010","unstructured":"Kumari R, Thappa DM. Comparative study of trichloroacetic acid versus glycolic acid chemical peels in the treatment of melasma. Indian J Dermatol Venereol Leprol. 2010;76(4):447.","journal-title":"Indian J Dermatol Venereol Leprol."},{"issue":"12","key":"488_CR77","first-page":"1439","volume":"10","author":"G Faghihi","year":"2011","unstructured":"Faghihi G, Shahingohar A, Siadat AH. Comparison between 1% tretinoin peeling versus 70% glycolic acid peeling in the treatment of female patients with melasma. J Drugs Dermatol. 2011;10(12):1439\u201342.","journal-title":"J Drugs Dermatol."},{"issue":"9","key":"488_CR78","first-page":"828","volume":"28","author":"R Sarkar","year":"2002","unstructured":"Sarkar R, Kaur C, Bhalla M, Kanwar AJ. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. Dermatol Surg. 2002;28(9):828\u201332.","journal-title":"Dermatol Surg."},{"issue":"1","key":"488_CR79","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1346-8138.2007.00211.x","volume":"34","author":"H Erbil","year":"2007","unstructured":"Erbil H, Sezer E, Ta\u015ftan B, Arca E, Kurumlu Z. Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma. J Dermatol. 2007;34(1):25\u201330.","journal-title":"J Dermatol."},{"issue":"1","key":"488_CR80","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/jocd.12260","volume":"16","author":"S Dayal","year":"2017","unstructured":"Dayal S, Sahu P, Dua R. Combination of glycolic acid peel and topical 20% azelaic acid cream in melasma patients: efficacy and improvement in quality of life. J Cosmet Dermatol. 2017;16(1):35\u201342.","journal-title":"J Cosmet Dermatol."},{"issue":"3","key":"488_CR81","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/DSS.0000000000000642","volume":"42","author":"R Sarkar","year":"2016","unstructured":"Sarkar R, Garg V, Bansal S, Sethi S, Gupta C. Comparative evaluation of efficacy and tolerability of glycolic acid, salicylic mandelic acid, and phytic acid combination peels in melasma. Dermatol Surg. 2016;42(3):384\u201391.","journal-title":"Dermatol Surg."},{"issue":"4","key":"488_CR82","first-page":"205","volume":"18","author":"A Ejaz","year":"2008","unstructured":"Ejaz A, Raza N, Iftikhar N, Muzzafar F. Comparison of 30% salicylic acid with Jessner\u2019s solution for superficial chemical peeling in epidermal melasma. J Coll Phys Surg Pak. 2008;18(4):205\u20138.","journal-title":"J Coll Phys Surg Pak."},{"issue":"6","key":"488_CR83","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jaad.2009.12.027","volume":"63","author":"S Kodali","year":"2010","unstructured":"Kodali S, Guevara IL, Carrigan CR, Daulat S, Blanco G, Boker A, Hynan LS, Pandya AG. A prospective, randomized, split-face, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women. J Am Acad Dermatol. 2010;63(6):1030\u20135.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"488_CR84","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/14764172.2017.1314501","volume":"19","author":"A Balevi","year":"2017","unstructured":"Balevi A, Ustuner P, \u00d6zdemir M. Salicylic acid peeling combined with vitamin C mesotherapy versus salicylic acid peeling alone in the treatment of mixed type melasma: a comparative study. J Cosmet Laser Ther. 2017;19(5):294\u20139.","journal-title":"J Cosmet Laser Ther."},{"issue":"4","key":"488_CR85","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1473-2165.2009.00471.x","volume":"8","author":"OA Azzam","year":"2009","unstructured":"Azzam OA, Leheta TM, Nagui NA, Shaarawy E, Hay RM, Hilal RF. Different therapeutic modalities for treatment of melasma. J Cosmet Dermatol. 2009;8(4):275\u201381.","journal-title":"J Cosmet Dermatol."},{"issue":"7","key":"488_CR86","first-page":"557","volume":"26","author":"F Murtaza","year":"2016","unstructured":"Murtaza F, Bangash AR, Khushdil A, Noor SM. Efficacy of trichloro-acetic acid peel alone versus combined topical magnesium ascorbyl phosphate for epidermal melasma. J Coll Phys Surg Pak. 2016;26(7):557\u201361.","journal-title":"J Coll Phys Surg Pak."},{"issue":"5","key":"488_CR87","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/DSS.0000000000001036","volume":"43","author":"AM Abdel-Meguid","year":"2017","unstructured":"Abdel-Meguid AM, Taha EA, Ismail SA. Combined Jessner solution and trichloroacetic acid versus trichloroacetic acid alone in the treatment of melasma in dark-skinned patients. Dermatol Surg. 2017;43(5):651\u20136.","journal-title":"Dermatol Surg."},{"issue":"9","key":"488_CR88","first-page":"1196","volume":"30","author":"CC Wang","year":"2004","unstructured":"Wang CC, Hui CY, Sue YM, Wong WR, Hong HS. Intense pulsed light for the treatment of refractory melasma in Asian persons. Dermatol Surg. 2004;30(9):1196\u2013200.","journal-title":"Dermatol Surg."},{"issue":"2","key":"488_CR89","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1524-4725.2010.01849.x","volume":"37","author":"MP Goldman","year":"2011","unstructured":"Goldman MP, Gold MH, Palm MD, Colon LE, Preston N, Johnson LA, Gottschalk RW. Sequential treatment with triple combination cream and intense pulsed light is more efficacious than sequential treatment with an inactive (control) cream and intense pulsed light in patients with moderate to severe melasma. Dermatol Surg. 2011;37(2):224\u201333.","journal-title":"Dermatol Surg."},{"issue":"5","key":"488_CR90","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1529-8019.2012.01530.x","volume":"25","author":"L Figueiredo Souza","year":"2012","unstructured":"Figueiredo Souza L, Trancoso Souza S. Single-session intense pulsed light combined with stable fixed-dose triple combination topical therapy for the treatment of refractory melasma. Dermatol Ther. 2012;25(5):477\u201380.","journal-title":"Dermatol Ther"},{"issue":"4","key":"488_CR91","first-page":"373","volume":"27","author":"JY Chung","year":"2016","unstructured":"Chung JY, Lee JH, Lee JH. Topical tranexamic acid as an adjuvant treatment in melasma: side-by-side comparison clinical study. J Dermatol Ther. 2016;27(4):373\u20137.","journal-title":"J Dermatol Ther"},{"issue":"1","key":"488_CR92","doi-asserted-by":"crossref","first-page":"13","DOI":"10.29271\/jcpsp.2018.01.13","volume":"28","author":"N Shakeeb","year":"2018","unstructured":"Shakeeb N, Noor SM, Ullah G, Paracha MM. Efficacy of intense pulse light therapy and triple combination cream versus intense pulse light therapy and triple combination cream alone in epidermal melasma treatment. J Coll Surg Pak. 2018;28(1):13\u20136.","journal-title":"J Coll Surg Pak."},{"issue":"8","key":"488_CR93","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/DSS.0000000000000057","volume":"40","author":"WJ Yun","year":"2014","unstructured":"Yun WJ, Moon HR, Lee MW, Choi JH, Chang SE. Combination treatment of low-fluence 1,064-nm Q-Switched Nd:YAG laser with novel intense pulse light in Korean melasma patients a prospective, randomized, controlled trial. Dermatol Surg. 2014;40(8):842\u201350.","journal-title":"Dermatol Surg."},{"issue":"5","key":"488_CR94","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/14764172.2015.1027227","volume":"17","author":"WJ Yun","year":"2015","unstructured":"Yun WJ, Lee SM, Han JS, Lee SH, Chang SY, Haw S, Lee JB, Won CH, Lee MW, Choi JH, Chang SE. A prospective, split-face, randomized study of the efficacy and safety of a novel fractionated intense pulsed light treatment for melasma in Asians. J Cosmet Laser Ther. 2015;17(5):259\u201366.","journal-title":"J Cosmet Laser Ther."},{"issue":"8","key":"488_CR95","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1365-2230.2011.04150.x","volume":"36","author":"KY Park","year":"2011","unstructured":"Park KY, Kim DH, Kim HK, Li K, Seo SJ, Hong CK. A randomized, observer-blinded, comparison of combined 1064-nm Q-switched neodymium-doped yttrium\u2013aluminum\u2013garnet laser plus 30% glycolic acid peel vs. laser monotherapy to treat melasma. J Clin Exp Dermatol Res. 2011;36(8):864\u201370.","journal-title":"J Clin Exp Dermatol Res."},{"issue":"6","key":"488_CR96","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3109\/14764172.2013.864201","volume":"16","author":"DB Lee","year":"2014","unstructured":"Lee DB, Suh HS, Choi YS. A comparative study of low-fluence 1,064\u00a0nm Q-Switched Nd: YAG laser with or without chemical peeling using Jessner\u2019s solution in melasma patients. J Cosmet Laser Ther. 2014;16(6):264\u201370.","journal-title":"J Cosmet Laser Ther."},{"issue":"7","key":"488_CR97","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/14764172.2017.1342036","volume":"19","author":"P Ustuner","year":"2017","unstructured":"Ustuner P, Balevi A, Ozdemir M. A split-face, investigator-blinded comparative study on the efficacy and safety of Q-switched Nd:YAG laser plus microneedling with vitamin C versus Q-switched Nd: YAG laser for the treatment of recalcitrant melasma. J Cosmet Laser Ther. 2017;19(7):383\u201390.","journal-title":"J Cosmet Laser Ther."},{"issue":"9","key":"488_CR98","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/DSS.0000000000001120","volume":"43","author":"C Kaminaka","year":"2017","unstructured":"Kaminaka C, Furukawa F, Yamamoto Y. The clinical and histological effect of a low-fluence Q-Switched 1,064-nm neodymium:yttrium-aluminum-garnet laser for the treatment of melasma and solar lentigines in asians prospective, randomized, and split-face comparative study. Dermatol Surg. 2017;43(9):1120\u201333.","journal-title":"Dermatol Surg."},{"issue":"6","key":"488_CR99","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1524-4725.2010.01523.x","volume":"36","author":"SY Jeong","year":"2010","unstructured":"Jeong SY, Shin JB, Yeo UC, Kim WS, Kim IH. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre-or post-treatment triple combination cream. Dermatol Surg. 2010;36(6):909\u201318.","journal-title":"Dermatol Surg."},{"issue":"1","key":"488_CR100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1524-4725.2009.01383.x","volume":"36","author":"P Wattanakrai","year":"2010","unstructured":"Wattanakrai P, Mornchan R, Eimpunth S. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064\u00a0nm) laser for the treatment of facial melasma in Asians. Dermatol Surg. 2010;36(1):76\u201387.","journal-title":"Dermatol Surg."},{"issue":"2","key":"488_CR101","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4103\/0378-6323.93633","volume":"78","author":"HK Kar","year":"2012","unstructured":"Kar HK, Gupta L, Chauhan A. A comparative study on efficacy of high and low fluence Q-switched Nd:YAG laser and glycolic acid peel in melasma. Indian J Dermatol Venereol Leprol. 2012;78(2):165.","journal-title":"Indian J Dermatol Venereol Leprol."},{"issue":"3","key":"488_CR102","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/14764172.2013.769274","volume":"15","author":"HS Kim","year":"2013","unstructured":"Kim HS, Kim EK, Jung KE, Park YM, Kim HO, Lee JY. A split-face comparison of low-fluence Q-switched Nd:YAG laser plus 1550\u00a0nm fractional photothermolysis vs. Q-switched Nd:YAG monotherapy for facial melasma in Asian skin. J Cosmet Laser Ther. 2013;15(3):143\u20139.","journal-title":"J Cosmet Laser Ther."},{"issue":"3 Pt 1","key":"488_CR103","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/dsu.12060","volume":"39","author":"JU Shin","year":"2013","unstructured":"Shin JU, Park J, Oh SH, Lee JH. Oral tranexamic acid enhances the efficacy of low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet laser treatment for melasma in Koreans: a randomized, prospective trial. Dermatol Surg. 2013;39(3 Pt 1):435\u201342.","journal-title":"Dermatol Surg."},{"issue":"4","key":"488_CR104","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40257-014-0080-x","volume":"15","author":"NY Jalaly","year":"2014","unstructured":"Jalaly NY, Valizadeh N, Barikbin B, Yousefi M. Low-power fractional CO2 laser versus low-fluence Q-switch 1,064\u00a0nm Nd:YAG laser for treatment of melasma: a randomized, controlled, split-face study. Am J Clin Dermatol. 2014;15(4):357\u201363.","journal-title":"Am J Clin Dermatol."},{"issue":"7","key":"488_CR105","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/jdv.12854","volume":"29","author":"V Vachiramon","year":"2015","unstructured":"Vachiramon V, Sirithanabadeekul P, Sahawatwong S. Low-fluence Q-switched Nd: YAG 1064-nm laser and intense pulsed light for the treatment of melasma. J Euro Acad Dermatol Venereol. 2015;29(7):1339\u201346.","journal-title":"J Euro Acad Dermatol Venereol."},{"issue":"4","key":"488_CR106","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/DSS.0000000000000304","volume":"41","author":"V Vachiramon","year":"2015","unstructured":"Vachiramon V, Sahawatwong S, Sirithanabadeekul P. Treatment of melasma in men with low-fluence Q-switched neodymium-doped yttrium\u2013aluminum\u2013garnet laser versus combined laser and glycolic acid peeling. Dermatol Surg. 2015;41(4):457\u201365.","journal-title":"Dermatol Surg."},{"issue":"9","key":"488_CR107","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/archdermatol.2011.255","volume":"147","author":"T Passeron","year":"2011","unstructured":"Passeron T, Fontas E, Kang HY, Bahadoran P, Lacour JP, Ortonne JP. Melasma treatment with pulsed-dye laser and triple combination cream: a prospective, randomized, single-blind, split-face study. Arch Dermatol. 2011;147(9):1106\u20138.","journal-title":"Arch Dermatol."},{"issue":"7","key":"488_CR108","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/lsm.20937","volume":"42","author":"BS Wind","year":"2010","unstructured":"Wind BS, Kroon MW, Meesters AA, Beek JF, van der Veen JW, Nieuweboer-Krobotov\u00e1 L, Bos JD, Wolkerstorfer A. Non-ablative 1,550\u00a0nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study. Lasers Surg Med. 2010;42(7):607\u201312.","journal-title":"Lasers Surg Med."},{"issue":"3","key":"488_CR109","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaad.2010.01.048","volume":"64","author":"MW Kroon","year":"2011","unstructured":"Kroon MW, Wind BS, Beek JF, Van Der Veen JW, Nieuweboer-Krobotov\u00e1 L, Bos JD, Wolkerstorfer A. Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study. J Am Acad Dermatol. 2011;64(3):516\u201323.","journal-title":"J Am Acad Dermatol."},{"issue":"6","key":"488_CR110","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1524-4725.1999.08248.x","volume":"25","author":"K Nouri","year":"1999","unstructured":"Nouri K, Bowes L, Chartier T, Romagosa R, Spencer J. Combination treatment of melasma with pulsed CO2 laser followed by Q-switched alexandrite laser: a pilot study. Dermatol Surg. 1999;25(6):494\u20137.","journal-title":"Dermatol Surg."},{"issue":"1","key":"488_CR111","first-page":"59","volume":"29","author":"S Angsuwarangsee","year":"2003","unstructured":"Angsuwarangsee S, Polnikorn N. Combined ultrapulse CO2 laser and Q-switched alexandrite laser compared with Q-switched alexandrite laser alone for refractory melasma: split-face design. Dermatol Surg. 2003;29(1):59\u201364.","journal-title":"Dermatol Surg."},{"issue":"4","key":"488_CR112","first-page":"315","volume":"9","author":"MA Trelles","year":"2010","unstructured":"Trelles MA, Velez M, Gold MH. The treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or a combination of the two: a comparative study. J Drugs Dermatol. 2010;9(4):315\u201322.","journal-title":"J Drugs Dermatol."},{"issue":"2","key":"488_CR113","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/14764172.2012.655287","volume":"14","author":"SP Hong","year":"2012","unstructured":"Hong SP, Han SS, Choi SJ, Kim MS, Won CH, Lee MW, Choi JH, Moon KC, Kim YJ, Chang SE. Split-face comparative study of 1550\u00a0nm fractional photothermolysis and trichloroacetic acid 15% chemical peeling for facial melasma in Asian skin. J Cosmet Laser Ther. 2012;14(2):81\u20136.","journal-title":"J Cosmet Laser Ther."},{"issue":"7","key":"488_CR114","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamadermatol.2014.5580","volume":"151","author":"H Hammami Ghorbel","year":"2015","unstructured":"Hammami Ghorbel H, Boukari F, Fontas E, Montaudi\u00e9 H, Bahadoran P, Lacour JP, Passeron T. Copper bromide laser vs triple-combination cream for the treatment of melasma: a randomized clinical trial. JAMA Dermatol. 2015;151(7):791\u20132.","journal-title":"JAMA Dermatol."},{"issue":"10","key":"488_CR115","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/lsm.22735","volume":"49","author":"YJ Choi","year":"2017","unstructured":"Choi YJ, Nam JH, Kim JY, Min JH, Park KY, Ko EJ, Kim BJ, Kim WS. Efficacy and safety of a novel picosecond laser using combination of 1 064 and 595\u00a0nm on patients with melasma: a prospective, randomized, multicenter, split-face, 2% hydroquinone cream-controlled clinical trial. Lasers Surg Med. 2017;49(10):899\u2013907.","journal-title":"Lasers Surg Med."},{"issue":"3","key":"488_CR116","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/14764172.2017.1376098","volume":"20","author":"T Chalermchai","year":"2018","unstructured":"Chalermchai T, Rummaneethorn P. Effects of a fractional picosecond 1,064\u00a0nm laser for the treatment of dermal and mixed type melasma. J Cosmet Laser Ther. 2018;20(3):134\u20139.","journal-title":"J Cosmet Laser Ther."},{"issue":"2","key":"488_CR117","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jaad.2016.03.001","volume":"75","author":"HC Lee","year":"2016","unstructured":"Lee HC, Thng TG, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis. J Am Acad Dermatol. 2016;75(2):385\u201392.","journal-title":"J Am Acad Dermatol."},{"key":"488_CR118","first-page":"3129","volume":"13","author":"N Sadako","year":"1979","unstructured":"Sadako N. Treatment of melasma with tranexamic acid. Clin Rep. 1979;13:3129\u201331.","journal-title":"Clin Rep."},{"key":"488_CR119","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2336\/nishinihonhifu.47.1101","volume":"47","author":"M Hajime","year":"1985","unstructured":"Hajime M, Mineo T, Yoshio T. Oral administration therapy with tranexamic acid for melasma. Nishinihon J Dermatol. 1985;47:1101\u20134.","journal-title":"Nishinihon J Dermatol."},{"key":"488_CR120","first-page":"676","volume":"30","author":"N Higashi","year":"1988","unstructured":"Higashi N. Treatment of melasma with oral tranexamic acid. Skin Res. 1988;30:676\u201380.","journal-title":"Skin Res."},{"key":"488_CR121","first-page":"178","volume":"3","author":"HJ Zhu","year":"2001","unstructured":"Zhu HJ, Yang XH. The clinical study of acidum tranexamicum on melasma. Pharm Prog. 2001;3:178\u201381.","journal-title":"Pharm Prog."},{"key":"488_CR122","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3126\/kumj.v10i4.10993","volume":"10","author":"D Karn","year":"2014","unstructured":"Karn D, Kc S, Amatya A, Razouria EA, et al. Oral tranexamic acid for the treatment of melasma. Kathmandu Univ Med J. 2014;10:40\u20133.","journal-title":"Kathmandu Univ Med J."},{"key":"488_CR123","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s00266-012-9899-9","volume":"36","author":"S Wu","year":"2012","unstructured":"Wu S, Shi H, Wu H, Yan S, et al. Treatment of melasma with oral administration of tranexamic acid. Aesthet Plast Surg. 2012;36:964\u201370.","journal-title":"Aesthet Plast Surg."},{"key":"488_CR124","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/jdv.12209","volume":"28","author":"Y Li","year":"2014","unstructured":"Li Y, Sun Q, He Z, Fu L, et al. Treatment of melasma with oral administration of compound tranexamic acid: a preliminary clinical trial. J Eur Acad Dermatol Venereol. 2014;28:393\u20134.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"2","key":"488_CR125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jocd.12291","volume":"16","author":"V Lajevardi","year":"2017","unstructured":"Lajevardi V, Ghayoumi A, Abedini R, Hosseini H, Goodarzi A, Akbari Z, Hedayat K. Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a short-term follow-up. J Cosmet Dermatol. 2017;16(2):235\u201342.","journal-title":"J Cosmet Dermatol."},{"key":"488_CR126","first-page":"520","volume":"60","author":"T Padhi","year":"2015","unstructured":"Padhi T, Pradhan S. Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: an open labeled randomized comparative trial. Indian J Dermatol. 2015;60:520.","journal-title":"Indian J Dermatol."},{"key":"488_CR127","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1111\/ajd.12474","volume":"58","author":"AW Tan","year":"2017","unstructured":"Tan AW, Sen P, Chua SH, Goh BK. Oral tranexamic acid lightens refractory melasma. Australas J Dermatol. 2017;58:e105\u20138.","journal-title":"Australas J Dermatol."},{"issue":"7","key":"488_CR128","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/ced.13164","volume":"42","author":"R Sharma","year":"2017","unstructured":"Sharma R, Mahajan VK, Mehta KS, Chauhan PS, Rawat R, Shiny TN. Therapeutic efficacy and safety of oral tranexamic acid and that of tranexamic acid local infiltration with microinjections in patients with melasma: a comparative study. Clin Exp Dermatol. 2017;42(7):728\u201334.","journal-title":"Clin Exp Dermatol."},{"key":"488_CR129","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12830","author":"MMT Colferai","year":"2018","unstructured":"Colferai MMT, Miquelin GM, Steiner D. Evaluation of oral tranexamic acid in the treatment of melasma. J Cosmet Dermatol. 2018. https:\/\/doi.org\/10.1111\/jocd.12830(Epub 9 Dec 2018).","journal-title":"J Cosmet Dermatol."},{"issue":"2","key":"488_CR130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jaad.2017.09.053","volume":"78","author":"E Del Rosario","year":"2018","unstructured":"Del Rosario E, Florez-Pollack S, Zapata L Jr, Hernandez K, Tovar-Garza A, Rodrigues M, Hynan LS, Pandya AG. Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma. J Am Acad Dermatol. 2018;78(2):363\u20139.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"488_CR131","doi-asserted-by":"crossref","first-page":"e12704","DOI":"10.1111\/dth.12704","volume":"31","author":"D Nagaraju","year":"2018","unstructured":"Nagaraju D, Bhattacharjee R, Vinay K, Saikia UN, Parsad D, Kumaran MS. Efficacy of oral tranexamic acid in refractory melasma: a clinico-immuno-histopathological study. Dermatol Ther. 2018;31(5):e12704.","journal-title":"Dermatol Ther."},{"issue":"8","key":"488_CR132","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1468-3083.2012.04464.x","volume":"27","author":"JI Na","year":"2013","unstructured":"Na JI, Choi SY, Yang SH, Choi HR, Kang HY, Park KC. Effect of tranexamic acid on melasma: a clinical trial with histological evaluation. J Eur Acad Dermatol Venereol. 2013;27(8):1035\u20139.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"7","key":"488_CR133","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2340\/00015555-2668","volume":"97","author":"HJ Kim","year":"2017","unstructured":"Kim HJ, Moon SH, Cho SH, Lee JD, Kim HS. Efficacy and safety of tranexamic acid in melasma: a meta-analysis and systematic review. Acta Derm Venereol. 2017;97(7):776\u201381.","journal-title":"Acta Derm Venereol."},{"issue":"3","key":"488_CR134","first-page":"13","volume":"7","author":"M Nestor","year":"2014","unstructured":"Nestor M, Bucay V, Callender V, Cohen JL, Sadick N, Waldorf H. Polypodium leucotomos as an adjunct treatment of pigmentary disorders. J Clin Aesthet Dermatol. 2014;7(3):13\u20137.","journal-title":"J Clin Aesthet Dermatol."},{"key":"488_CR135","unstructured":"Martin LK, Caperton C, Woolery-Lloyd H, et al. A randomized double-blind placebo-controlled study evaluating the effectiveness and tolerability of oral Polypodium leucotomos in patients with melasma. American Academy of Dermatology Annual Meeting: 16\u201320 March 2012; San Diego."},{"issue":"8","key":"488_CR136","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamadermatol.2013.4294","volume":"149","author":"AM Ahmed","year":"2013","unstructured":"Ahmed AM, L\u00f3pez I, Perese F, et al. A randomized, double-blinded, placebo-controlled trial of oral Polypodium leucotomos extract as an adjunct to sunscreen in the treatment of melasma. JAMA Dermatol. 2013;149(8):981\u20133.","journal-title":"JAMA Dermatol."},{"issue":"3","key":"488_CR137","first-page":"14","volume":"11","author":"CL Goh","year":"2018","unstructured":"Goh CL, Chuah SY, Tien S, Thng G, Vitale MA, Delgado-Rubin A. Double-blind, placebo-controlled trial to evaluate the effectiveness of Polypodium leucotomos extract in the treatment of melasma in asian skin: a pilot study. J Clin Aesthet Dermatol. 2018;11(3):14\u20139.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"8","key":"488_CR138","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1365-4632.2009.04130.x","volume":"48","author":"EB Handog","year":"2009","unstructured":"Handog EB, Galang DA, de Leon-Godinez MA, Chan GP. A randomized, double-blind, placebo-controlled trial of oral procyanidin with vitamins A, C, E for melasma among Filipino women. Int J Dermatol. 2009;48(8):896\u2013901.","journal-title":"Int J Dermatol."},{"issue":"2","key":"488_CR139","first-page":"164","volume":"2","author":"WL Teo","year":"2015","unstructured":"Teo WL, Gan E, Jinghan A, Chuah SY, Alain K, et al. Double blind placebo controlled trial to evaluate of the effectiveness of a dietary supplement rich in carotenoids as adjunct to topical lightening cream for the treatment of melasma: a pilot study. Pigment Disord. 2015;2(2):164.","journal-title":"Pigment Disord."},{"issue":"11","key":"488_CR140","first-page":"1469","volume":"34","author":"R Bissonnette","year":"2008","unstructured":"Bissonnette R, Nigen S, Bolduc C, M\u00e9ry S, Nocera T. Protection afforded by sunscreens containing inorganic sunscreening agents against blue light sensitivity induced by aminolevulinic acid. Dermatol Surg. 2008;34(11):1469\u201376.","journal-title":"Dermatol Surg."},{"key":"488_CR141","first-page":"30","volume":"8","author":"SA Hamadi","year":"2009","unstructured":"Hamadi SA, Mohammed MM, Aljaf AN, Abdulrazak A. The role of topical and oral melatonin in management of melasma patients. J Arab Univ Basic Appl Sci. 2009;8:30\u201342.","journal-title":"J Arab Univ Basic Appl Sci."},{"issue":"2","key":"488_CR142","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jaad.2015.09.024","volume":"74","author":"BE Cohen","year":"2016","unstructured":"Cohen BE, Elbuluk N. Microneedling in skin of color: a review of uses and efficacy. J Am Acad Dermatol. 2016;74(2):348\u201355.","journal-title":"J Am Acad Dermatol."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00488-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-019-00488-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00488-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T13:04:36Z","timestamp":1665147876000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-019-00488-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,4]]},"references-count":142,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["488"],"URL":"https:\/\/doi.org\/10.1007\/s40257-019-00488-w","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737068323.793569257","asserted-by":"object"}]},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,4]]},"assertion":[{"value":"4 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This article has no funding source.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jacqueline-McKesey, Andrea Tovar-Garza and Amit G. Pandya have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}